MicroRNA-26b protects against MASH development and can be efficiently targeted with lipid nanoparticles
‘Metabolic dysfunction-associated steatotic liver disease’ (MASLD), formerly known as non-alcohol fatty liver disease (NAFLD) [1], is the most common form of fatty liver disease. It accounts for roughly 25% of liver-disease cases globally and is defined by …